FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Will the tills ring for Iovance?
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
A roundup of the first quarter's key oncology drug approvals and rejections.
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
